PHS
ERAS icon

PFM Health Sciences’s Erasca ERAS Stock Holding History

PFM Health Sciences’s Portfolio ERAS Stock Details ERAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,072,224
Closed -$1.36M – 78
2025
Q2 		$1.36M Sell
1,072,224
-2,417,335
-69% -$3.24M 0.12% 53
2025
Q1 		$4.78M Sell
3,489,559
-900,868
-21% -$1.55M 0.35% 43
2024
Q4 		$11M Sell
4,390,427
-486,484
-10% -$1.33M 0.68% 42
2024
Q3 		$13.3M Buy
4,876,911
+205,137
+4% +$578K 0.75% 34
2024
Q2 		$11M Buy
4,671,774
+2,136,672
+84% +$4.61M 0.55% 46
2024
Q1 		$5.22M Sell
2,535,102
-40,409
-2% -$80.8K 0.25% 67
2023
Q4 		$5.49M Sell
2,575,511
-1,355,122
-34% -$2.86M 0.33% 51
2023
Q3 		$7.74M Sell
3,930,633
-866,827
-18% -$2.22M 0.36% 59
2023
Q2 		$13.2M Hold
4,797,460
– – 0.51% 53
2023
Q1 		$14.4M Hold
4,797,460
– – 0.64% 53
2022
Q4 		$20.7M Sell
4,797,460
-2,467,521
-34% -$16.7M 0.74% 51
2022
Q3 		$56.7M Buy
7,264,981
+1,383,599
+24% +$11.1M 2.05% 13
2022
Q2 		$32.8M Buy
5,881,382
+1,089,976
+23% +$7.13M 1.25% 36
2022
Q1 		$41.2M Sell
4,791,406
-399,999
-8% -$4.63M 1.54% 28
2021
Q4 		$77M Hold
5,191,405
– – 2.62% 10
2021
Q3 		$98.2M Buy
+5,191,405
New +$107M 2.89% 7

Other funds holding ERAS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PFM Health Sciences's ERAS Position: Q3 2025 in Review

PFM Health Sciences sold out of Erasca (ERAS) in Q3 2025, closing a stake of 1,072,224 shares — an estimated $1.36M sold.

PFM Health Sciences first reported a position in ERAS in Q3 2021 and held it in 16 quarters. The position peaked at $98.2M in Q3 2021. 141 funds tracked by Wall St. Rank hold ERAS as of Q3 2025.

  • PFM Health Sciences reported no remaining Erasca position as of Q3 2025 after selling out during the quarter.
  • PFM Health Sciences sold 1,072,224 Erasca shares in Q3 2025, an estimated $1.36M.
  • PFM Health Sciences first reported a position in Erasca in Q3 2021 and held it in 16 quarters.
  • PFM Health Sciences's Erasca position peaked at $98.2M in Q3 2021.
  • 141 funds tracked by Wall St. Rank held Erasca as of Q3 2025.

Based on PFM Health Sciences's 13F filing for Q3 2025, filed 14 Nov 2025.